Dow Venture Capital - the investment arm of the Dow Chemical Company - is focused on pursuing strategic investments in attractive start-up companies around the world that enable and accelerate Dow's business growth and value. Their investment portfolio works to reflect the diversity of Dow Chemical's business interests, investing in start-up companies in various stages of maturity within key markets.
Dow Venture Capital supports their investment strategy by investing in external innovation in areas of strategic interest and pursuing new technologies that enable new business opportunities for Dow Chemical. Dow Venture Capital works to invest in promising businesses and technologies addressing many of the world's most challenging problems, such as the need for clean water, renewable energy generation and conservation, and increasing agricultural productivity.
They exited their investments in Noxxon Pharma, Entropic and PathScale.
Ken Van Heel
Executive Vice President